Contineum Therapeutics starts Phase 2 trial of PIPE-791 for IPF; 324 subjects, completion June 2028

Contineum Therapeutics, Inc.

Submitted Phase 2 trial details for PIPE-791 to ClinicalTrials.gov; expects ~324 IPF patients enrolled globally.
Trial is 26-week, randomized, dose-ranging, double-blind, placebo-controlled, once-daily dosing.
Primary efficacy endpoint: change from baseline in forced vital capacity (FVC) at week 26.
Trial design informed by regulatory feedback and completed Phase 1 data; completion expected June 2028.
No financial guidance or capital structure changes included in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.